Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.47 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920137 | 0.79 | MAPT (0.59) | LMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6187314 | 0.73 | HTR6 (0.78) | HTR6 | |
| SCHEMBL6187103 | 0.72 | HTR6 (0.85) | HTR6 | |
| Hydrochloric Acid SCHEMBL6185720 | 0.72 | HTR6 (0.77) | HTR6 | |
| SCHEMBL834704 | 0.72 | ALDH1A1 (0.65) | LMNAKDM4EALDH1A1MDM2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6189713 | 0.72 | HTR6 (0.83) | HTR6 | |
| SCHEMBL6979091 | 0.71 | HTR6 (0.79) | HTR6 | |
| SCHEMBL3618100 | 0.70 | HTR6 (0.65) | HTR6KDM4EALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL3621246 | 0.70 | HTR6 (0.64) | HTR6KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL6187705 | 0.69 | HTR6 (1.00) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | HTR6 949/4885LMNA 1170/4885KDM4E 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.